KIRK RANDAL J, 10% Owner, subtracted 345,897 shares of Histogenics Corporation (HSGX) from its portfolio at the rate of $0.15 per share valuing $51,885 on Jan 15. The insider left behind 1,692,366 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Histogenics Corporation (HSGX) was $0.19. Currently, the 1st Resistance Point for this stock is $0.20, with a 2nd Resistance Point sitting at $0.21. Meanwhile, this company’s stock has a 1st Support Level at $0.18 and a 2nd Support Level at $0.17. Histogenics Corporation (HSGX) stock has gained 0.21%, in the past five days. In the past three months, this stock’s price has risen by $0.01, or 4.79%. This year-to-date, Histogenics Corporation (HSGX) shares have gained $0.10, or 114.11%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Histogenics Corporation (HSGX) stock, 25% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, Hold % of medium-term indicators point to this stock being a “.” Looking further ahead, 100 – 200 Day MACD Oscillator % of long-term indicators suggest that this stock is a “.”
With 94,599 K shares outstanding, this company currently has a market capitalization of $18,229K. Histogenics Corporation (HSGX) generates annual net income of -$8,640 K. This stock has generated a 1-Year Total Return of -91.90%, a 3-Year Total Return of -90.36%, and a 5-year Total Return of 0.00%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is -$0.01 per share. This estimate came from a total of 1 Wall Street Analysts. Of those market experts, the high estimate was -$0.01 and the low estimate was -$0.01. In the year-ago quarter, Histogenics Corporation (HSGX) generated per-share earnings of -$0.25. If the analysts are correct about the current quarter’s earnings, the growth will be +96.00%.
Turning our focus now to insider trading activity, there have been 0 purchases (0 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 8 insider buys amounting to 3,647,431 shares and 0 insider sales amounting to 0 shares. In the past full year, 9 insider purchases were made (involving 3,878,199 shares) and 2 insider sell-offs equivalent to 652,307 shares.
Moving onto liquidity, Histogenics Corporation (HSGX) has a Current Ratio of 5.71, a Quick Ratio of 5.71 and a Cash Ratio of 5.41.